Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: An Observational Study in A Chinese PopulationOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This observational study asked how HIV-1 infection reshapes the gut bacterial community in a Chinese population. Researchers profiled fecal microbiota as a proxy for gut microbiota. They used barcoded 454-pyrosequencing of the 16S rRNA gene V1-V3 regions. They compared healthy controls, untreated patients, and patients on antiretroviral therapy. Serum cytokines were also measured to link taxa to inflammation.
Who was studied?
The cohort was 83 men from Zhejiang, China, enrolled in 2014. It included 67 HIV-1-infected patients and 16 age-matched, sex-matched healthy volunteers. Among the patients, 35 were antiretroviral-naive and 32 had received therapy for over one year. Participants were under 60, had a body mass index below 30, and used no antibiotics or probiotics in the prior month. Only male patients were enrolled.
What were the most important findings?
Overall bacterial diversity did not differ significantly between patients and controls (Shannon and Simpson indices, p greater than 0.05). However composition shifted clearly. The Firmicutes to Bacteroidetes ratio rose to 1.351 in patients versus 0.482 in controls (p less than 0.05). Prevotella was prevalent in infected patients, while Bacteroidaceae dominated controls. Phascolarctobacterium, Clostridium XIVb, Dialister, and Megamonas correlated with inflammatory cytokines such as TNF-alpha and IL-6. After therapy the viral load fell, but the ratio stayed high at 1.751 (p less than 0.01), showing dysbiosis was not reversed.
What are the greatest implications of this study?
The findings suggest gut dysbiosis is a durable feature of HIV-1 infection that short-term antiretroviral therapy does not fully correct. Specific taxa tied to inflammatory cytokines may mark or sustain immune activation. This points toward microbiota-targeted adjuncts, such as prebiotics or probiotics, as possible strategies. The cross-sectional, male-only design cannot establish whether dysbiosis causes or follows infection.